Search results for "Transporter"

showing 10 items of 676 documents

Effects of Sodium dependent Glucose Transporter 2 (SGLT2) Inhibition with Empagliflozin on Oxidative Stress and Endothelial Dysfunction in STZ-Induce…

2013

medicine.medical_specialtyChemistryDiabetic ratmedicine.diseasemedicine.disease_causeBiochemistryEndocrinologyGLUCOSE TRANSPORTER 2Physiology (medical)Internal medicinemedicineEmpagliflozinEndothelial dysfunctionSodium dependentOxidative stressFree Radical Biology and Medicine
researchProduct

Use of Novel Antidiabetic Agents in Patients with Type 2 Diabetes and COVID-19: A Critical Review

2021

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19). The latter is a pandemic that has the potential of developing into a severe illness manifesting as systemic inflammatory response syndrome, acute respiratory distress syndrome, multi-organ involvement and shock. In addition, advanced age and male sex and certain underlying health conditions, like type 2 diabetes mellitus (T2DM), predispose to a higher risk of greater COVID-19 severity and mortality. This calls for an urgent identification of antidiabetic agents associated with more favourable COVID-19 outcomes among patients with T2DM, as well as recognition of their potential underlying…

medicine.medical_specialtyCoronavirus disease 2019 (COVID-19)1 receptor agonists Sodium-glucose co-transporter&nbspEndocrinology Diabetes and MetabolismSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)COVID-19 Dipeptidyl peptidase&nbspReviewType 2 diabetesSodium-glucose co-transporter 2 inhibitorsType 2 diabetesGlucagon-like peptide 1 receptor agonistsDiabetes mellitusPandemicInternal Medicinemedicine2 diabetesIntensive care medicineAntidiabetic agents4 inhibitors Glucagon-like peptide&nbspbusiness.industryCOVID-19medicine.diseaseSystemic inflammatory response syndromeShock (circulatory)Dipeptidyl peptidase 4 inhibitorsmedicine.symptombusiness2 inhibitors Type&nbspDiabetes Therapy
researchProduct

SGLT2 inhibitors in T2D and associated comorbidities - differentiating within the class

2019

Abstract Background For patients with type 2 diabetes (T2D), cardiovascular disease (CVD) is the single most common cause of mortality. In 2008 and 2012, the Federal Drug Administration (FDA) and the European Medicines Agency (EMA) respectively mandated cardiovascular outcomes trials (CVOTs) on all new anti-diabetic agents, as prospective trials statistically powered to rule out excess cardiovascular risk in patients with T2D. Unexpectedly, some of these CVOTs have demonstrated not only cardiovascular safety, but also cardioprotective effects, as was first shown for the SGLT2 inhibitor empagliflozin in EMPA-REG OUTCOME. Expert opinion To debate newly available CVOT data and to put them into…

medicine.medical_specialtyDiabetes mellitus type 2 ; drug therapy ; Cardiovascular diseases ; drug therapy ; Canagliflozin ; therapeutic use ; Benzhydryl compounds ; therapeutic use ; Glucosides ; therapeutic use ; Sodium-Glucose Transporter 2 Inhibitors ; therapeutic useEndocrinology Diabetes and MetabolismEmpagliflozin610 Medicine & health030209 endocrinology & metabolismContext (language use)ComorbidityType 2 diabetesDiseaseCanagliflozin ; Cardiovascular disease ; Dapagliflozin ; Empagliflozin ; SGLT2 inhibitor ; Type 2 diabetes.lcsh:Diseases of the endocrine glands. Clinical endocrinology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineDiabetes mellitusCorrespondenceEmpagliflozinHumansMedicine030212 general & internal medicineCanagliflozinDapagliflozinIntensive care medicineSodium-Glucose Transporter 2 InhibitorsCanagliflozinlcsh:RC648-665business.industryIncidence616.379-008.64 [udc]Type 2 diabetesSGLT2 inhibitorGeneral MedicineDapagliflozinCardiovascular diseasePrognosismedicine.disease3. Good healthEastern europeanDiabetes Mellitus Type 2chemistryCardiovascular Diseasesbusinessmedicine.drug
researchProduct

Association analysis between gene variants of the tyrosine hydroxylase and the serotonin transporter in borderline personality disorder.

2010

For patients with borderline personality disorder (BPD), we previously reported an independent effect of the catechol-o-methyl-transferase (COMT) low-activity (Met(158)) allele and an interaction with the low-expression allele of the deletion/insertion (short/long or S/L, resp.) polymorphism in the serotonin transporter-linked promoter region (5-HTTLPR). The purpose of the present study was to extend these findings to the tyrosine hydroxylase (TH) Val(81)Met single nucleotide polymorphism (SNP), the 5-HTTLPR S/L polymorphism incorporating the recently described functional A/G SNP within the long allele of the 5-HTTLPR (rs25531) as well as the variable number of tandem repeat (VNTR) polymorp…

medicine.medical_specialtyGenotypeTyrosine 3-MonooxygenaseGenome-wide association studySingle-nucleotide polymorphismCatechol O-MethyltransferasePolymorphism Single NucleotidePolymorphism (computer science)Borderline Personality DisorderInternal medicinemental disordersGenotypemedicineSNPHumansAlleleBiological PsychiatrySerotonin transporterAllelesGenetic associationGeneticsSerotonin Plasma Membrane Transport ProteinsbiologyGenetic VariationDiagnostic and Statistical Manual of Mental DisordersPsychiatry and Mental healthEndocrinologyCase-Control Studiesbiology.proteinPsychologyGenome-Wide Association StudyThe world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry
researchProduct

Influence of polyunsaturated fatty acids on Cortisol transport through MDCK and MDCK-MDR1 cells as blood-brain barrier in vitro model.

2011

Abstract Transport across the blood–brain barrier is a relevant factor in the pharmacological action of many drugs and endogenous substances whose action site is located in brain. An overactive P-gp has been suggested to be of relevance for the resistance of the HPA system to be suppressed by glucocorticoids, which is one of the best described biological abnormalities in certain types of depression. PUFA acids have shown clinical efficacy in depressed patients and the hypothesis is that these compounds are able to reduce HPA axis activity as this effect has been shown in animal models of depression. The objective of the present work was (1) to characterize Cortisol transport through MDCK an…

medicine.medical_specialtyHydrocortisonePharmaceutical ScienceEndogenyBiologyIn Vitro TechniquesBlood–brain barrierModels BiologicalPermeabilityCell LineDogsInternal medicineAnimal models of depressionmedicineAnimalschemistry.chemical_classificationTight junctionTransporterFlow CytometryIn vitromedicine.anatomical_structureEndocrinologychemistryBlood-Brain BarrierFatty Acids UnsaturatedEffluxPolyunsaturated fatty acidEuropean journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
researchProduct

Sodium-glucose cotransporter 2 inhibition : towards an indication to treat diabetic kidney disease

2020

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have clearly demonstrated their beneficial effect in diabetic kidney disease (DKD) on top of the standard of care [blood glucose control, renin–angiotensin system blockade, smoking cessation and blood pressure (BP) control], even in patients with overt DKD. However, the indication of this drug class is still blood glucose lowering in type 2 diabetic patients with estimated glomerular filtration rate >45mL/min/1.73m2. Based on the new evidence, several scientific societies have emphasized the preferential prescription of SGLT2i for patients at risk of heart failure or kidney disease, but still within the limits set by health authorities. A r…

medicine.medical_specialtyMedicina030232 urology & nephrologyRenal functionReviewsType 2 diabetes030204 cardiovascular system & hematologyDiabetic nephropathy03 medical and health sciences0302 clinical medicineSodium-Glucose Transporter 2Internal medicineDiabetes mellitusDiabetic nephropathiesmedicineChronic renal failureHumansDiabetic NephropathiesDiabetic kidney diseaseESRDSodium-Glucose Transporter 2 InhibitorsTransplantationbusiness.industryType 2 diabetesNefropaties diabètiquesmedicine.diseasePrognosisBlood pressureDiabetes Mellitus Type 2NephrologyHeart failureSodium/Glucose Cotransporter 2Insuficiència renal crònicabusinessSGLT2 inhibitorsKidney disease
researchProduct

Cl−uptake promoting depolarizing GABA actions in immature rat neocortical neurones is mediated by NKCC1

2004

GABA is the principal inhibitory neurotransmitter in the mature brain, but during early postnatal development the elevated [Cl−]i in immature neocortical neurones causes GABAA receptor activation to be depolarizing. The molecular mechanisms underlying this intracellular Cl− accumulation remain controversial. Therefore, the GABA reversal potential (EGABA) or [Cl−]i in early postnatal rat neocortical neurones was measured by the gramicidin-perforated patch-clamp method, and the relative expression levels of the cation−Cl− cotransporter mRNAs (in the same cells) were examined by semiquantitative single-cell multiplex RT-PCR to look for statistical correlations with [Cl−]i. The mRNA expression …

medicine.medical_specialtyNeocortexPhysiologyGABAA receptorDepolarizationBiologygamma-Aminobutyric acidEndocrinologymedicine.anatomical_structureGiant depolarizing potentialsInternal medicinemedicinePatch clampCotransporterReversal potentialmedicine.drugThe Journal of Physiology
researchProduct

Dexamethasone suppresses eNOS and CAT-1 and induces oxidative stress in mouse resistance arterioles

2004

Long-term treatment with glucocorticoids is associated with mild to moderate hypertension. We reported previously that downregulation of endothelial NO synthase (eNOS) expression and activity is likely to contribute to this increase in blood pressure. In the present study, we tested the effects of dexamethasone on the vasodilation of microvascular arterioles using implanted dorsal skin-fold chambers in anesthetized C57BL/6J mice. Experiments were performed on control mice or on mice treated with dexamethasone (0.1–3 mg/kg of body wt). Endothelium-dependent vasodilation in response to ACh (0.1–10 μM) was reduced by dexamethasone in a dose-dependent fashion. Comparable inhibition was seen in …

medicine.medical_specialtyNitric Oxide Synthase Type IIIPhysiologyNitric Oxide Synthase Type IIAscorbic AcidBiologyArgininemedicine.disease_causeAntioxidantsDexamethasoneMicrocirculationMiceDownregulation and upregulationEnosArteriolePhysiology (medical)medicine.arteryInternal medicinemedicineAnimalsHumansGlucocorticoidsCells CulturedNitritesDexamethasoneCationic Amino Acid Transporter 1NitratesMyocardiumEndothelial Cellsbiology.organism_classificationAcetylcholineMice Inbred C57BLVasodilationNitric oxide synthaseArteriolesOxidative StressEndocrinologybiology.proteinVascular ResistanceNitric Oxide SynthaseCardiology and Cardiovascular MedicineOxidative stressGlucocorticoidmedicine.drugAmerican Journal of Physiology-Heart and Circulatory Physiology
researchProduct

Early, but not late onset estrogen replacement therapy prevents oxidative stress and metabolic alterations caused by ovariectomy.

2014

Aims: The usefulness of estrogen replacement therapy (ERT) in preventing oxidative stress associated with menopause is controversial. We aimed to study if there is a critical time window for effective treatment of the effects of ovariectomy with estrogens at the molecular, metabolic, and cellular level. Results: Our main finding is that early, but not late onset of ERT prevents an ovariectomy-associated increase in mitochondrial hydrogen peroxide levels, oxidative damage to lipids and proteins, and a decrease in glutathione peroxidase and catalase activity in rats. This may be due to a change in the estrogen receptor (ER) expression profile: ovariectomy increases the ER α/β ratio and immedi…

medicine.medical_specialtyPhysiologymedicine.drug_classGlucose uptakeOvariectomyClinical BiochemistryGlucose Transport Proteins FacilitativeEstrogen receptorMitochondria LiverBiologymedicine.disease_causeBiochemistryAntioxidantsInternal medicinemedicineAnimalsMetabolomicsMolecular BiologyGeneral Environmental Sciencechemistry.chemical_classificationEstradiolGlutathione peroxidaseEstrogen Replacement TherapyGlucose transporterBrainCell BiologyHydrogen Peroxidemedicine.diseaseRatsMenopauseOxidative StressOriginal Research CommunicationsEndocrinologyGlucosechemistryEstrogenCatalasebiology.proteinGeneral Earth and Planetary SciencesFemaleOxidative stressAntioxidantsredox signaling
researchProduct

Influence of prenatal exposure to environmental pollutants on human cord blood levels of glutamate

2013

El pdf del artículo es la versión post-print.

medicine.medical_specialtyPlacentaGlutamic AcidTransport010501 environmental sciencesToxicologyPolychlorobiphenyl (PCB)01 natural sciencesUmbilical cord03 medical and health scienceschemistry.chemical_compoundGlutamatergicGlutamate Plasma Membrane Transport Proteins0302 clinical medicinePregnancyPlacentaInternal medicinemedicineHydrocarbons ChlorinatedHumansMethylmercury0105 earth and related environmental scienceschemistry.chemical_classificationChemistryGeneral NeuroscienceGlutamate receptorMethylmercuryHexachlorobenzeneMercuryFetal Blood3. Good healthAmino acidmedicine.anatomical_structureEndocrinologyBiochemistryExcitatory Amino Acid Transporter 213. Climate actionMaternal ExposureCord bloodOrganochlorine pesticidesEnvironmental PollutantsFemaleGlutamate030217 neurology & neurosurgery
researchProduct